Search company, investor...

Founded Year

1981

Stage

Grant | Alive

Total Raised

$1.05M

Valuation

$0000 

Last Raised

$1.05M | 7 yrs ago

Revenue

$0000 

About Genzyme

Genzyme, a biotechnology company, engages in the discovery and development of products and services primarily in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases, and endocrinology.

Headquarters Location

50 Binney St

Cambridge, Massachusetts, 02142,

United States

617-252-7500

Loading...

Loading...

Genzyme Patents

Genzyme has filed 626 patents.

The 3 most popular patent topics include:

  • molecular biology
  • biotechnology
  • rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/29/2019

2/20/2024

Molecular biology, Experimental cancer drugs, Monoclonal antibodies, MicroRNA, Fluoroarenes

Grant

Application Date

7/29/2019

Grant Date

2/20/2024

Title

Related Topics

Molecular biology, Experimental cancer drugs, Monoclonal antibodies, MicroRNA, Fluoroarenes

Status

Grant

Latest Genzyme News

STAT+: A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived

Feb 20, 2024

Kristoffer Tripplaar/Sipa via AP Images A U.S. appeals court revived a controversial lawsuit brought by nearly two dozen people who claimed they were harmed by a contaminated rare disease medicine sold by a Sanofi subsidiary and a subsequent rationing plan that only worsened their health. And if some upcoming procedural hurdles are cleared, the suit may shine a light on an unusual patient dilemma when a drug is in short supply. The case stems from a troubling episode involving Genzyme which, at one point, sold the only treatment in the U.S. to combat Fabry disease, a rare neurological disorder that causes heart and kidney problems. But a pair of high-profile manufacturing gaffes discovered more than a decade ago led to a long-running legal battle with patients, a debate over handling drug shortages, and, ultimately, a takeover by Sanofi. advertisement The difficulties began in June 2009, when viral contamination was found at a facility, prompting Genzyme to suspend production and ration supplies of its drug, called Fabrazyme. A few months later, Food and Drug Administration inspectors found stainless steel fragments , rubber from vial stoppers, and fiber-like material from the manufacturing process. The discovery exacerbated the shortages. Get unlimited access to award-winning journalism and exclusive events.

Genzyme Frequently Asked Questions (FAQ)

  • When was Genzyme founded?

    Genzyme was founded in 1981.

  • Where is Genzyme's headquarters?

    Genzyme's headquarters is located at 50 Binney St, Cambridge.

  • What is Genzyme's latest funding round?

    Genzyme's latest funding round is Grant.

  • How much did Genzyme raise?

    Genzyme raised a total of $1.05M.

  • Who are the investors of Genzyme?

    Investors of Genzyme include Cystic Fibrosis Foundation, Sanofi, SV Health Investors and Oak Investment Partners.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.